Bayer Taps Clinical Chief, Sells Stivarga and Goes Carbon-Free in Spain

Bayer promotes Dr. Christoph Koenen to Chief Medical Officer while selling Stivarga to Grünenthal for up to EUR 375 million and issuing EUR 2 billion in hybrid bonds.

Bayer has handed Dr. Christoph Koenen the role of Chief Medical Officer, effective October 1, a promotion that leaves him juggling two jobs at once. Koenen keeps his existing post as Head of Clinical Development and Operations for the Pharmaceuticals division while taking on the medical chief's brief. The appointment lands as the Leverkusen group pushes its development pipeline forward and reshapes its balance sheet at the same time.

On the portfolio side, the company has agreed to sell the cancer drug Stivarga to Aachen-based Grünenthal for as much as EUR 375 million, a deal struck in September and still subject to customary regulatory clearances. Divestments of that kind let Bayer shed mature medicines, free up cash and sharpen its focus within pharma. The group is also leaning on debt markets: in September it placed hybrid bonds totaling EUR 2 billion across two 30-year tranches, lifting the outstanding hybrid total to EUR 6.55 billion.

Pipeline Wins and a New Menopause Alliance

Progress in drug development has come on several fronts. The FDA accepted a supplemental approval application for the candidate Lynkuet under an accelerated review, while the Lemiretprocel program picked up orphan-drug status. Bayer also launched the Menopause Advocacy and Policy Alliance in late September, an international coalition aimed at reforming care and education. In consumer health, the group rolled out a recyclable mono-material blister pack for Talcid in Germany.

Industrial modernization is running in parallel. Bayer has invested EUR 17 million in its Aspirin active-ingredient plant in Langreo, Spain, where a new energy system is entering test operation and is due to move into regular service before the end of 2026. Management says the site will become the first fully decarbonized pharmaceutical production facility in Spain, avoiding more than 6,500 tonnes of carbon dioxide a year and cutting process emissions from the legacy medicine to nearly zero. Bayer bills it as one of the first decarbonized pharma plants in Europe, a move meant to keep the site competitive over the long haul and ready for tighter environmental rules. The project earned recognition this week through the Convive awards run by utility Iberdrola.

Across the Atlantic, the consumer business added MiraSOFT, a stool softener built on docusate sodium, sold exclusively through CVS Pharmacy in more than 7,000 stores and via the chain's online channel. Bayer is also hunting for outside science: at a Bayer Co.Lab showcase tied to a Boston conference, Asian biotech firms presented their RNA technologies, with the group's business development and licensing teams scouting for partnerships.

JPMorgan Caution and Missouri Litigation Weigh on the Stock

The operational headlines have not shielded the equity. The shares fell 5.1% yesterday to close at EUR 45.31, pressured in part by a cautious call from JPMorgan. Analyst Richard Vosser argued that early consensus estimates for the third quarter look too optimistic. Legal risk added to the nerves, with a fresh Roundup case in Missouri where plaintiffs again challenged the herbicide's safety and product design as a verdict was pending.

Those US courtroom battles and regulatory demands continue to dampen investor sentiment, according to media reports. Even so, Bayer stock changes hands at EUR 45.30 and is up 22% since the start of the year. Market participants will get a clearer read on operations on November 3, when the company reports third-quarter results — a print expected to show how the pharma revamp and the recent financing moves are feeding through to the numbers.